Answers are grounded in this paper and cite their sources.
Background Refractory mucous membrane pemphigoid (MMP) is increasingly treated with rituximab, but the evidence rests on small, heterogeneous series. We estimated pooled rates of complete remission, disease control, and relapse. Methods We searched MEDLINE, Embase, and Scopus from inception to May 2026 for studies of MMP treated with rituximab (≥3 patients each). Outcomes were mapped to the 2015 consensus and pooled as logit-transformed proportions using random-effects models with REML estimation of between-study variance. Pre-specified subgroup and sensitivity analyses were performed, together with an additional CR analysis according to treatment status (PROSPERO CRD420261401818). Results Twenty-five studies (445 patients, predominantly retrospective) were included. Complete remission was 68% (95% CI 58–76%; I 2 = 65%); when restricted to patients off therapy or on no more than minimal or minimal-adjuvant therapy, it was 45% (35–56%) and disease control 85% (81–88%; I 2 = 0%); among those in complete remission, 40% relapsed (34–46%). Outcomes in patients with ocular involvement were similar to the whole cohort. Complete remission was more frequent with the lymphoma than the rheumatoid-arthritis protocol (P = 0.037). Serious adverse events and infections were each reported in about 10% of patients. Conclusions Rituximab was associated with high remission and disease-control rates in MMP, but relapse remained common and the optimal maintenance or retreatment strategy remains uncertain. The regimen difference is hypothesis-generating and requires randomized confirmation. Evidence certainty is limited by uncontrolled study designs. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261401818.
No takes yet. Share an insight, caveat, or question.
Tartaglia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: